| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAV3 |
| Uniprot No | P56539 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-83aa |
| 氨基酸序列 | MMAEEHTDLEAQIVKDIHCKEIDLVNRDPKNINEDIVKVDFEDVIAEPVG TYSFDGVWKVSYTTFTVSKYWCYRLLSTLLGVP |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CAV3重组蛋白的模拟参考文献示例(注：实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: *"Recombinant Expression and Functional Characterization of Human Caveolin-3 in Escherichia coli"*
**作者**: Smith J, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达人源CAV3重组蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并验证其形成脂筏结构的能力，为后续结构解析提供基础。
---
2. **文献名称**: *"Caveolin-3 Recombinant Protein Restores Membrane Integrity in a Muscular Dystrophy Cell Model"*
**作者**: Lee H, et al.
**摘要**: 利用昆虫细胞系统表达重组CAV3蛋白，发现其能修复因CAV3突变导致的肌细胞膜损伤，并通过体外实验证明其改善细胞膜稳定性及信号传导功能。
---
3. **文献名称**: *"Interactions of Recombinant Caveolin-3 with Dystrophin-Glycoprotein Complex in Cardiomyocytes"*
**作者**: Gonzalez R, et al.
**摘要**: 研究在哺乳动物细胞中表达重组CAV3.结合免疫共沉淀技术，揭示了CAV3与肌营养不良蛋白复合物的直接相互作用，提示其在维持心肌细胞膜完整性中的关键作用。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词 **"recombinant Caveolin-3 protein"** 或 **"Caveolin-3 expression and purification"**，并筛选近5年研究以获取最新进展。
**Background of CAV3 Recombinant Protein**
Caveolin-3 (CAV3) is a muscle-specific protein belonging to the caveolin family, integral to forming caveolae—small, flask-shaped invaginations in the plasma membrane. These structures are critical for cellular processes such as signal transduction, lipid homeostasis, and membrane trafficking. CAV3 is predominantly expressed in skeletal and cardiac muscles, where it interacts with signaling molecules (e.g., nitric oxide synthase, G-proteins) to regulate muscle contraction, metabolism, and stress responses.
Mutations in the *CAV3* gene are linked to multiple myopathies, including limb-girdle muscular dystrophy, rippling muscle disease, and cardiomyopathies. These mutations often disrupt caveolae formation, leading to membrane instability, impaired signaling, and muscle degeneration. Studying CAV3’s molecular mechanisms is thus vital for understanding disease pathogenesis.
Recombinant CAV3 proteins are engineered using heterologous expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional CAV3 for research and therapeutic applications. They retain key domains, such as the scaffolding domain essential for protein interactions, enabling studies on CAV3’s structure-function relationships, post-translational modifications, and disease-associated variants.
In drug discovery, recombinant CAV3 serves as a tool for screening molecules that modulate caveolae-dependent pathways or stabilize mutant proteins. It also aids in developing gene therapies targeting *CAV3* mutations. Furthermore, it is used to generate antibodies for diagnostic assays, enhancing detection of CAV3-related disorders.
Overall, CAV3 recombinant protein bridges basic research and clinical innovation, offering insights into muscle biology and advancing therapeutic strategies for caveolinopathies.
×
